The financials
Integra LifeSciences Holdings Corporation by the numbers
Integra LifeSciences Holdings Corporation (IART) reported revenue of $392M in Q1 2026 (quarter ended March 31, 2026), up 2.4% from the same quarter a year earlier. That came with a gross margin of 55% and net loss of $4.6M. For the full year FY2025, revenue was $1.64B (+1.5% year on year) and net income −$516M. Its largest product in 2026-Q1 was Neurosurgery at $198M, 51% of the disclosed total, just ahead of Regenerative Skin And Wound at 20%.
| Income statement | Q1 2026 | Q1 2025 | Change |
|---|---|---|---|
| Revenue | $392M | $383M | +2.4% |
| Gross profit | $217M | $194M | +12% |
| Operating income | $11M | −$15M | to a profit |
| Net income | −$4.6M | −$25M | n/a |
| Diluted EPS | −$0.06 | −$0.33 | n/a |
| Product | Revenue | Share |
|---|---|---|
| Neurosurgery | $198M | 51% |
| Regenerative Skin And Wound | $80M | 20% |
| Instruments | $47M | 12% |
| ENT | $38M | 9.6% |
| Private Label | $29M | 7.4% |
Business Segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Q1 2026Total $391.9M (-2.5%)
Private Label grew +7.1% year on yearInstruments -7.3% year on year
Segment Latestquarter on quarteryear on year
- Neurosurgery$198.2M$198.2MQoQ -1.7%year on year +3.8%-1.7%+3.8%
- Regenerative Skin And Wound$79.6M$79.6MQoQ -5.2%year on year +6.5%-5.2%+6.5%
- Instruments$47.2M$47.2MQoQ -5.8%year on year -7.3%-5.8%-7.3%
- ENT$37.7M$37.7MQoQ -7.7%year on year -2.8%-7.7%-2.8%
- Private Label$29.1M$29.1MQoQ +14%year on year +7.1%+14%+7.1%